Ginkgo Bioworks Holdings (DNA) FCF Margin (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly FCF Margin came in at 232.65% in Q2 2026, down 12969.0% on a YoY basis from N/an in Q2 2025, and up 6.82% quarter-over-quarter from 249.66% in Q1 2026.
Powered by 
Analysis
Ginkgo Bioworks Holdings (DNA) FCF Margin (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has reported FCF Margin for 7 consecutive years, with 232.65% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, FCF Margin fell 12969.0% year-over-year to 232.65%; the trailing twelve-month figure through Jun 2026 stood at 156.26% (down 2587.0% YoY), and the FY2025 full-year result was 105.04%, up 6327.0% from the prior year.
- FCF Margin climbed to 232.65% in Q2 2026 per DNA's latest filing, from 249.66% in the prior quarter.
- Across five years, FCF Margin topped out at 13.94% in Q1 2022 and bottomed at 252.92% in Q1 2024.
- Historically, FCF Margin has averaged 131.75% across 5 years, with a median of 132.81% in 2022.
- The sharpest annual moves came in 2022 and 2026: FCF Margin jumped 14495 bps in 2022, then tumbled 12969 bps in 2026.
- Over 5 years, FCF Margin stood at 132.45% in 2022, then surged by 81 bps to 25.21% in 2023, then plunged by 408 bps to 128.05% in 2024, then declined by 12 bps to 142.78% in 2025, then plunged by 63 bps to 232.65% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 232.65%, 249.66%, and 142.78% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.06 Bn | 42.11 Bn | 1.44 Bn | 8.24% |
| 2 | Medpace Holdings | 16.50 Bn | 16.00 Bn | 201.64 Mn | 19.52% |
| 3 | Charles River Laboratories International | 13.77 Bn | 13.62 Bn | 452.07 Mn | 14.80% |
| 4 | Icon | 12.62 Bn | 11.69 Bn | 479.29 Mn | 15.69% |
| 5 | Fortrea Holdings | 1.68 Bn | 1.51 Bn | 139.20 Mn | 2.93% |
| 6 | Evotec SE | 661.34 Mn | 235.46 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 442.79 Mn | 358.26 Mn | 18.44 Mn | -232.65% |
| 8 | Champions Oncology | 72.49 Mn | 72.62 Mn | 7.03 Mn | -16.17% |
| 9 | MindWalk Holdings | 61.66 Mn | 53.38 Mn | 1.82 Mn | -58.25% |
| 10 | VivoSim Labs | 1.47 Mn | 1.47 Mn | - | -17,977.78% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -232.65% |
| Mar 31, 2026 | -249.66% |
| Dec 31, 2025 | -142.78% |
| Sep 30, 2025 | -81.38% |
| Jun 30, 2025 | -102.96% |
| Mar 31, 2025 | -154.70% |
| Dec 31, 2024 | -128.05% |
| Sep 30, 2024 | -133.18% |
| Jun 30, 2024 | -198.24% |
| Mar 31, 2024 | -252.92% |
| Dec 31, 2023 | -25.21% |
| Sep 30, 2023 | -140.60% |
| Jun 30, 2023 | -108.07% |
| Mar 31, 2023 | -136.34% |
| Dec 31, 2022 | -132.45% |
| Sep 30, 2022 | -63.00% |
| Jun 30, 2022 | -75.36% |
| Mar 31, 2022 | -13.94% |
| Dec 31, 2021 | -114.92% |
| Sep 30, 2021 | -13.75% |